A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

NCT00771251 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

311

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: CNTO 148
DRUG: Placebo

Sponsor

Janssen Pharmaceutical K.K.

Collaborators

[object Object]